Best Neurology Companies in Florida, United States
The 64 best Neurology companies in Florida, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AAVANTIBio.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Florida
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | AAVANTIBio Developer of gene transfer therapies for neuromuscular disease | $107M | 68 mo ago | 57 | — | 54 patents Viral gene‑therapy vectors targeting inherited cardiomyopathies and optimized Kozak expression tools | — |
| 2 | AxoGen Developer of therapies for the repair of peripheral nerve injuries | $96M | 115 mo ago | 809 809 → 607 (-25%) | Karen Zaderej President | 560 patents Peripheral nerve repair and regeneration using specialized biomaterial grafts and protective devices | — |
| 3 | CatalystPharma Developing therapies for people with rare debilitating diseases | $52M | 136 mo ago | 167 167 → 182 (+9%) | Hubert Huckel Co-Founder | — | — |
| 4 | NovaVision Non-invasive device for vision restoration in stroke survivors | $38M | 233 mo ago | — | — | 64 patents Vision therapy and testing devices integrating optical and electrical stimulation | — |
| 5 | Enveric Developer of small-molecule therapeutics for the treatment of neuropsychiatric disorders 42Funding top 29%News top 30%Growth top 31%Talent bottom 49% All 9 signals ▾Fundingtop 29% Newstop 30% Growthtop 31% Talentbottom 49% Fin. healthbottom 42% Techbottom 38% Globalbottom 38% Marketbottom 36% Moatbottom 36% Funding: Raised $26.4M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) News: 15 BI events in 12 mo (of 35 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 2 mo ago | 25 | Joseph Tucker CEO | — | — |
| 6 | Keystone Heart Embolic cerebral protection devices | $14M | 145 mo ago | 33 | — | — | — |
| 7 | Vycor Medical Innovative neurosurgical and neurotherapeutic solutions improving lives through advanced medical devices | $12M | 113 mo ago | 6 | — | — | — |
| 8 | ADvantage Therapeutics Developer of immunotherapies for neurological disorders | $10M | 35 mo ago | 2 | Jeffrey Madden CEO | — | — |
| 9 | Metallomix Developer of metal-based therapies to treat neurological disorders | $10M | 33 mo ago | — | Santosh Kesari Co-Founder | — | — |
| 10 | Stimwave Developer of smart devices for neuropathic pain monitoring | $10M | 69 mo ago | 143 | Aure Bruneau CEO | 29 patents Wireless implantable neural stimulation using patch antenna technology for spinal nerve modulation | — |
| 11 | Envoy Therapeutics Developer of therapeutics for neurological and psychiatric diseases | $8M | 169 mo ago | 19 | Christophe Weber CEO | — | — |
| 12 | Charleston Laboratories Pharmaceutical company focused on preventing opioid-induced nausea and vomiting | $7M | 164 mo ago | 3 | Paul Bosse Founder & CEO | 46 patents Formulating combined opioid analgesic and antiemetic pharmaceutical compositions. | — |
| 13 | PsyBio Therapeutics Developer of drugs for treating mental illness and neurological disorders | $6M | 42 mo ago | 5 | Noah Davis Co-Founder | — | — |
| 14 | DemeRx Developer of non-addicting alternatives for opioid de-addiction | $5M | 133 mo ago | 4 | Deborah Mash Founder & CEO | 296 patents Ibogaine-derived compounds for opioid addiction and withdrawal therapy | — |
| 15 | Jupiter Neurosciences Developer of therapeutics for the treatment of neuroinflammation | $3M | 50 mo ago | 5 | Marsh Hayward Co-Founder | 2 patents Formulation and therapeutic use of resveratrol-based pharmaceutical compositions. | — |
| 16 | Myosin Therapeutics Developer of therapeutics for CNS-based disorders | $3M | 10 mo ago | 8 | Courtney Miller Co-Founder | — | — |
| 17 | Archer Pharmaceuticals Late Clinical stage drug discovery and development biopharma focused on Alzheimers disease | $3M | 92 mo ago | 11 | Michael Mullan Founder & CEO | — | — |
| 18 | Psilera Manufacturer of natural-based medicines for the treatment of mental health illnesses | $2M | 59 mo ago | 9 | Jackie Salm Co-Founder | 29 patents Pharmaceutical formulations of tryptamine derivatives and 5‑HT2A receptor ligands | — |
| 19 | NeuraWell Developer of therapeutics for neurological diseases | $2M | 25 mo ago | — | Magid Abraham Co-Founder & CEO | — | — |
| 20 | Sinapis Pharma Treatment for stroke and brain injury using a neuroprotective agent | $2M | 146 mo ago | — | Donald Picker CEO | — | — |
| 21 | Serodopa Therapeutics Developer of novel CNS disorder treatments using prodrug technology and repurposed drugs | $2M | 20 mo ago | — | Jackson Streeter Co-Founder | — | — |
| 22 | InNeuroCo Intermediate catheters and super distal access device for neurovascular surgery | $2M | 108 mo ago | 99 | Marc Litzenberg Founder & CEO | — | — |
| 23 | Pasithea Developer of treatments for psychiatric and neurological disorders | $1M | 55 mo ago | 15 | Lawrence Steinman Co-Founder | — | — |
| 24 | Asha Therapeutics Developer of therapeutics for neurodegenerative diseases | $1M | 47 mo ago | — | Bradlee Heckmann Co-Founder & CSO | — | — |
| 25 | Adolore Biotherapeutics Developer of non-opioid analgesics for the treatment of pain | $1M | 9 mo ago | — | Joseph Glorioso Founder | — | — |
| 26 | Vector Vitale Developer of bio-molecule-based therapeutics for the treatment of oncology and other degenerative diseases | $1M | 49 mo ago | 4 | Victor Vedovato Managing Director | 103 patents Anti‑aging nutraceuticals and pharma compositions targeting homeostasis, inflammation, and viral defense | — |
| 27 | Longeveron Developer of cellular therapies for aging-related and life-threatening conditions | $1M | 3 mo ago | 23 23 → 41 (+78%) | Joshua Hare Co-Founder | 84 patents Mesenchymal stem cell therapies and potency assays for neurodegenerative and immune disorders | — |
| 28 | Myolyn FES bikes empowering movement for individuals with muscle weakness or paralysis | $1M | 69 mo ago | 12 12 → 8 (-33%) | Matthew Bellman Founder & Chief Technology Officer | — | — |
| 29 | Relox Medical Drugs for the treatment and recovery from traumatic brain injury and stroke | $700K | 194 mo ago | — | — | — | — |
| 30 | Deinde Medical Provider of neuro-interventional tool for minimally invasive brain surgery | $515K | 31 mo ago | — | Prattipati Laxminarain CEO | — | — |
| 31 | Nanoantibiotics Developer of therapeutics for liver disease and neurological disorders | $500K | 155 mo ago | — | Elliot Ehrlich CEO | 3 patents Nano-formulated therapeutic agents for ascites treatment | — |
| 32 | Tautatis LRRK2 inhibitor for neurodegenrative disorders | $448K | 214 mo ago | — | Hanno Roder Founder & President | 21 patents Therapeutic pharmaceutical compositions targeting cancer and tauopathy diseases. | — |
| 33 | Powers Medical Devices Device to promote non-nutritive sucking in preterm babies | $350K | 142 mo ago | 11 | — | — | — |
| 34 | Croton Healthcare Global leader in functional brain imaging solutions and MEG technology | $325K | 88 mo ago | — | Gordon Baltzer CEO | — | — |
| 35 | Optima Neuro Developer of a electroencephalography device for diagnosing neurological disorders | $265K | 85 mo ago | 4 | Ryan Kern CEO | — | — |
| 36 | EEG NOW Immediate EEG technology for rapid brain injury assessment and treatment | $250K | 86 mo ago | — | Richard Allen CEO | — | — |
| 37 | EndoUVtech Developer of a UV laser system for stroke treatment | $200K | 16 mo ago | — | Chip Vurst Co-Founder & CEO | — | — |
| 38 | Vova Ida Therapeutics Developer of drugs for Alzheimers | $100K | 44 mo ago | 2 | Corinne Lasmezas Founder | — | — |
Top 12 Neurology companies in Florida
#1
Public · Naples, Florida · founded 1994 · 25 employees$26.4Mraised▾
Developer of small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company leverages discovery and development platform Psybrary developing combination therapies with chemotherapeutic agents and immunotherapies for anxiety, depression, and addiction disorders.
- Apr 2026Post IPO$5M
- Apr 2023Post IPO$12.8M
- Aug 2022Post IPO$8.6M
#2
Public · Miami, Florida · founded 2014 · 23 employees$1.1Mraised▾
Developer of cellular therapies for aging-related and life-threatening conditions. The company's product include Lomecel-B is derived from culture-expanded medicinal signaling cells harvested from the bone marrow of adult human donors. It is used for the treatment of aging frailty, Alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
- Mar 2026Post IPO$15.9M
- Dec 2021Post IPO$20.5M
- Feb 2020Seed$100K
- Nov 2018Grant (prize money)$6.7M
#3
Seed · Jupiter, Florida · founded 2020 · 8 employees$3Mraised▾
Developer of therapeutics for CNS-based disorders. The company has small molecule modulators which include MT-125 for different cancers, MT-110 for METH use disorders, and other substance use disorders.
- Aug 2025Grant (prize money)$4.5M
- Apr 2025Grant (prize money)$3M
- Mar 2025Grant (prize money)$1.5M
- Feb 2025Seed$3M
#4
Seed · Delray Beach, Florida · founded 2021$1.3Mraised▾
Developer of non-opioid analgesics for the treatment of pain. The company is focused on the development of gene therapies that are opioid-free anti-pain therapies (DMAPs). The company has two gene therapy product candidates for patients suffering from Erythromelalgia and osteoarthritis knee pain.
- Sep 2025Seed$25K
- Dec 2023Seed$1.1M
- Jan 2022Seed$250K
#5
Funding Raised · Gainesville, Florida · founded 2023$1.5Mraised▾
Developer of novel CNS disorder treatments using prodrug technology and repurposed drugs. The company focuses on developing new therapies for central nervous system disorders. Its lead programs utilize prodrug technology and repurposed drugs to address unmet medical needs, including drug overdose reversal and medical countermeasures. The company employs an agile and efficient approach to drug development and approval.
- Sep 2024Grant (prize money)$1.5M
#6
Acquired · Gainesville, Florida · founded 2017 · 57 employees$107Mraised▾
Developer of gene transfer therapies for neuromuscular disease. The has developed gene-editing technologies to improve the lives of people living with fatal diseases. The company's lead program uses an AAV-mediated gene transfer therapy targeting Friedreich’s ataxia(FA).
- Oct 2020Series A$107M
- Seed—
#7
Public · Alachua, Florida · founded 2002 · 809 employees$96.4Mraised▾
Developer of therapies for the repair of peripheral nerve injuries. The flagship product is the AVANCE Nerve Graft, a human allograft nerve for treating damaged peripheral nerves. Other products include AxoGuard Nerve Connector and Protector (extracellular matrices), and AxoTouch Two-Point Discriminator tool, a set of two aluminum discs to measure sensation after a nerve injury.
- Oct 2016Conventional Debt$31M
- Aug 2015Series D$17.1M
- Nov 2014Series D$1.8M
- Oct 2012Series D$20.8M
#8
Seed · Miami, Florida · founded 2021$10Mraised▾
Developer of metal-based therapies to treat neurological disorders. The company is involved in research and have developed a platform called PtS3-MetalloMix for metal speciation analysis. The company has developed pipeline of therapeutics for Parkinson's, Alzheimer's, Lewy Body Dementia, and Friedreich's Ataxia.
- Sep 2023Seed$10M
- Oct 2021Seed$1.2M
#9
Series B · Miami, Florida · founded 2021 · 2 employees$10.2Mraised▾
Developer of immunotherapies for neurological disorders. It offers a lead candidate Alhydrogel AD04 an immuno-stimulant that is used as an adjuvant in human and animal vaccination programs for the treatment of Alzheimer's disease.
- Jul 2023Series B$13.7M
#10
Seed · Oakland Park, Florida · founded 2022$200Kraised▾
Developer of a UV laser system for stroke treatment. This system integrates with existing stroke procedures to minimize post-stroke side effects and recurring strokes. The technology safely dilates arteries and dissolves inaccessible clots, improving patient recovery. It adds minimal time to current procedures and works alongside existing devices. The system's unique capabilities reduce permanent side effects such as paralysis, dementia, and speech impairment. Patents protect the technology and method. Successful animal and human trials support its efficacy and pave the way for market entry.
- Feb 2025Seed$200K
#11
Seed · Boca Raton, Florida · founded 2018$1.6Mraised▾
Developer of therapeutics for neurological diseases
#12
Acquired · Coral Gables, Florida · founded 2002 · 167 employees$52.5Mraised▾
Developing therapies for people with rare debilitating diseases. The company focused on the development and commercialization of prescription drugs targeting rare neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome, infantile spasms and Tourette’s disorder.
- Feb 2015Post IPO$37.4M
- Sep 2013Post IPO$15.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neurotech in Florida is moving
A read on the academic research around Neurotech in Florida — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 569 papers.
- University of Florida313
- Mayo Clinic in Florida137
- Florida College66
- University of South Florida50
- University of Florida Health41
- Thalamus2→4
- Neural Prosthesis1→3
- Deep brain stimulation12→13
- Parkinson's disease2→3
- Deep brain stimulation65→100
- Neuromodulation5→22
- Neuroscience28→44
- Epilepsy1→17
- Stimulation24→39
- Neuromodulation2→7
- Neuroscience12→15
- Brain stimulation4→7
- Intensive care medicine1→3
- Tourette syndrome1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.